Equities

Oculis Holding AG

Oculis Holding AG

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)14.76
  • Today's Change0.01 / 0.07%
  • Shares traded39.61k
  • 1 Year change+49.92%
  • Beta-0.0389
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.

  • Revenue in USD (TTM)0.00
  • Net income in USD-78.53m
  • Incorporated2022
  • Employees36.00
  • Location
    Oculis Holding AGBahnhofstrasse 7ZUG 6300SwitzerlandCHE
  • Phone+41 217113970
  • Websitehttps://oculis.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Tourmaline Bio Inc0.00-48.85m582.60m44.00--1.81-----1.68-1.680.0012.520.00----0.00-20.37---21.05--------------0.00------42.99------
Chromadex Corp91.67m1.49m582.80m106.00403.0616.88250.566.360.01890.01891.210.45211.673.0523.51864,792.402.70-42.114.08-65.1461.4559.681.62-30.642.35--0.0004--15.9921.5070.15---36.66--
Immunome Inc10.13m-305.35m586.73m55.00--2.65--57.93-6.06-6.060.18893.560.0579----184,163.60-174.46-94.54-212.48-112.66-----3,014.59-1,403.15----0.00-------184.68--29.52--
Mineralys Therapeutics Inc0.00-153.25m590.26m28.00--2.49-----3.27-3.270.004.760.00----0.00-56.16---61.19--------------0.00-------141.28------
Stoke Therapeutics Inc16.74m-105.46m596.94m110.00--2.57--35.65-2.10-2.100.32944.380.0628--42.55152,209.10-39.56-31.62-46.04-33.92-----629.86-1,775.50----0.00---29.22---3.59--11.56--
Altimmune Inc52.00k-103.52m597.35m59.00--4.48--11,487.53-1.55-1.550.00081.880.0003--0.0798881.36-65.84-39.62-70.44-42.58-----199,076.90-1,811.89----0.00--726.47-47.15-4.41---45.92--
Dianthus Therapeutics Inc5.37m-67.09m599.93m53.00--1.76--111.80-2.49-2.490.196811.510.0196--3.13101,245.30-24.54-41.40-25.91-44.70-----1,250.32-12,132.27----0.00------43.04---57.21--
Oculis Holding AG0.00-78.53m615.74m36.00--5.76-----2.01-2.010.002.560.00----0.00-54.70---68.03-------------138.750.0129-------129.47------
ORIC Pharmaceuticals Inc0.00-119.87m643.35m112.00--2.35-----1.81-1.810.003.880.00----0.00-41.59-33.92-44.71-35.77------------0.00-------12.99--10.09--
AnaptysBio Inc57.17m-165.66m644.18m117.00--7.64--11.27-6.07-6.072.092.770.1166--7.39488,649.60-33.78-18.08-36.91-18.96-----289.75-269.21----0.00--66.7827.97-27.11---5.36--
Adaptive Biotechnologies Corp177.28m-195.24m644.92m709.00--2.88--3.64-1.34-1.341.211.520.27784.684.92250,045.10-30.61-19.69-35.66-22.0658.4667.18-110.19-122.273.38--0.3725---8.1125.06-12.52--11.11--
Arbutus Biopharma Corp6.74m-76.70m655.64m73.00--6.13--97.25-0.4259-0.42590.03740.56430.0451--3.5792,356.16-51.29-52.62-59.50-58.11-----1,137.65-537.81----0.00---53.5125.00-4.89---2.40--
BIOAGE Labs Inc0.00-62.16m661.05m58.00---------1.82-1.820.004.26---------------------------4.990.0724-------60.75------
Tectonic Therapeutic Inc0.00-54.39m661.43m13.00--4.40-----13.91-13.910.0010.200.00----0.00-38.96-45.22-42.77-49.14------------0.0066------111.48---66.27--
Data as of Nov 22 2024. Currency figures normalised to Oculis Holding AG's reporting currency: US Dollar USD

Institutional shareholders

2.60%Per cent of shares held by top holders
HolderShares% Held
abrdn, Inc.as of 30 Sep 2024820.55k1.97%
Landsbr�f hfas of 07 Nov 2024102.22k0.25%
Banque Lombard Odier & Cie SA (Investment Management)as of 30 Sep 202495.75k0.23%
Merrill Lynch, Pierce, Fenner & Smith, Inc. (Invt Mgmt)as of 30 Sep 202418.26k0.04%
UBS Financial Services, Inc.as of 30 Sep 202417.45k0.04%
Geode Capital Management LLCas of 30 Sep 202414.94k0.04%
Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 202413.57k0.03%
UBS Securities LLCas of 30 Sep 2024332.000.00%
Bank of America, NA (Private Banking)as of 30 Sep 202455.000.00%
DuPont Capital Management Corp.as of 30 Sep 20244.000.00%
More ▼
Data from 30 Sep 2024 - 07 Nov 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.